Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL-007 + TDF/Entecavir in Chronic Hepatitis B
NCT04157257Phase 2Unknown
- Sponsor
- Qilu Pharmaceutical
- Start
- Jul 2019
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of QL-007 in Chronic Hepatitis B (CHB) (4 arms), sponsored by Qilu Pharmaceutical. Primary endpoint: Main index of pharmacodynamics at 24 weeks. Status: unknown.
02
Drugs
QL-007
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT04157257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04157257.